Перспективы применения колхицина в медицине: новые данные
https://doi.org/10.14412/1995-4484-2020-183-190
Аннотация
Иммуновоспалительные заболевания (ИВЗ; immune-mediated inflammatory disease) относятся к числу наиболее тяжелых хронических болезней человека. Ведущими механизмами развития ИВЗ в широком смысле слова являются аутоиммунный и/или аутовоспалительный иммунопатологические процессы, для первого из которых характерно преобладание активации приобретенного, а для второго – врожденного иммунитета. Для лечения ИВЗ применяется широкий спектр противовоспалительных лекарственных препаратов, доминирующим универсальным эффектом которых, независимо от их структуры и «молекулярных» мишеней, является подавление воспаления. Особое место занимает колхицин, представляющий собой алкалоидный экстракт из растения Colchicum autumnale (безвременник осенний), который применяется для лечения воспаления суставов более 2 тыс. лет и обладает уникальными, не до конца расшифрованными механизмами, определяющими его «противовоспалительный» и анальгетический эффект. Благодаря расшифровке «молекулярных» механизмов действия колхицина в отношении подавления аутовоспалительных механизмов иммунопатогенеза ИВЗ интерес к колхицину существенно возрос и способствовал расширению показаний для его применения в медицине.
Об авторах
З. С. Алекберова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
115522, Москва, Каширское шоссе, 34А
119991, Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251-60. doi: 10.1136/pgmj.2006.052688
2. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-24. doi: 10.1038/ni.3731
3. Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832-42. doi: 10.1038/ni.3777
4. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:1242-8. doi: 10.1371/journal.pmed.0030297
5. Kahlenberg JM, Kang I. Clinicopathologic significance of inflammasome activation in autoimmune diseases. Arthritis Rheum. 2019 Sep 28. doi: 10.1002/art.41127
6. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
7. Насонов ЕЛ. Новые направления фармакотерапии иммуновоспалительных ревматических заболеваний. Терапевтический архив. 2019;91(8):98-107. doi: 10.26442/00403660.2019.08.000406 [Nasonov EL. New directions of pharmacotherapy of immuneinflammatory rheumatic diseases. Therapeutic Archive. 2019;91(8):98-107. doi: 10.26442/00403660.2019.08.000406 (In Russ.)].
8. Hernandez-Santana YE, Giannoudaki E, Leon G, et al. Current perspectives on the interleukin-1 family as targets for inflammatory disease. Eur J Immunol. 2019;49(9):1306-20. doi: 10.1002/eji.201848056
9. Roubille F, Kritikou E, Busseuil D, et al. Colchicine: an old wine in a new bottle? Antiinflam Antiallerg Agents Med Chem. 2013;12:14-23. doi: 10.2174/1871523011312010004
10. Leung YY, Yao Hui LL, Kraus VB. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341-50. doi: 10.1016/j.semarthrit.2015.06.013
11. Angelidis C, Kotsialou Z, Kossyvakis C, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24(6):659-63. doi: 10.2174/138161282466618012
12. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407-20. doi: 10.1038/nri.2016.58
13. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-52. doi: 10.1038/nrd3800
14. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32. doi: 10.1038/s41584-019-0277-8
15. Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi: 10.14412/1995-4484-2016-60-77
16. Stack J, Ryan J, McCarthy G. Colchicine: New Insight to an old drug. Am J Ther. 2015;22(5):e151-157. doi: 10.1097/01.mjt.0000433937.07244.e1
17. Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi: 10.1038/s41572-019-0115-y 18. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev. 2010;233(1):218-32. doi: 10.1111/j.0105-2896.2009.00860.x
18. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465-79. doi: 10.1016/j.clinthera.2014.07.017
19. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-4. doi: 10.1111/j.1445-5994.1987.tb01232.x
20. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi: 10.1002/art.27327
21. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447-61. doi: 10.1002/acr.21773
22. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29-42. doi: 10.1136/annrheumdis-2016-209707
23. Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.
24. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32.
25. Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609-14. doi: 10.1002/art.1780170517
26. Karimzadeh H, Nazari J, Mottaghi P, Kabiri P. Different duration of Colchicine for preventing recurrence of gouty arthritis. J Res Med Sci. 2006;11:104-7.
27. Roddy E, Mallen CD; CONTACT trial authors. Naproxen or low-dose colchicine for gout flares in primary care? Response to: 'Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care' by Parperis et al. Ann Rheum Dis. 2019 Dec 4. doi: 10.1136/annrheumdis-2019-216671
28. Wortmann RL, MacDonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32:2386-97. doi: 10.1016/j.clinthera.2011.01.008
29. Елисеев МС. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017;55(6):600-9. doi: 10.14412/1995-4484-2017-600-609
30. McCarthy GM, Dunne A. Calcium crystal deposition diseases – beyond gout. Nat Rev Rheumatol. 2018;14(10):592-602. doi: 10.1038/s41584-018-0078-5
31. Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70:571-5. doi: 10.1136/ard.2010.139360
32. Владимиров СА, Елисеев МС. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-52. doi: 10.14412/1995-4484-2018-746-752
33. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020;72(2):220-33. doi: 10.1002/art.41142
34. Migliore A, Gigliucci G, Alekseeva L, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019 Dec 19;11:1759720X19893800. doi: 10.1177/1759720X19893800
35. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011
36. Conway R, McCarthy GM. Calcium-containing crystals and osteoarthritis: an unhealthy alliance. Curr Rheumatol Rep. 2018;20(3):13. doi: 10.1007/s11926-018-0721-9
37. Frallonardo P, Ramonda R, Peruzzo L, et al. Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. Clin Rheumatol. 2018;37(10):2847-53. doi: 10.1007/s10067-018-4166-3
38. McAllister MJ, Chemaly M, Eakin AJ, et al. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthritis Cartilage. 2018;26(5):612-9. doi: 10.1016/j.joca.2018.02.901
39. Ghouri A, Conaghan PG. Treating osteoarthritis pain: recent approaches using pharmacological therapies. Clin Exp Rheumatol. 2019;37 Suppl 120(5):124-9.
40. Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000Res. 2019 Jun 21;8. doi: 10.12688/f1000research.18831.1
41. Mobasheri A, van Spil WE, Budd E, et al. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr Opin Rheumatol. 2019;31(1):80-9. doi: 10.1097/BOR.0000000000000567
42. Еzen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253. doi: 10.3389/fimmu.2017.00253
43. Grattagliano I, Bonfrate L, Ruggiero V, et al. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther. 2014;95(1):89-97. doi: 10.1038/clpt.2013.148
44. El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF). Orphanet J Rare Dis. 2019;14(1):224. doi: 10.1186/s13023-019-1201-7
45. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644-51. doi: 10.1136/annrheumdis-2015-208690
46. Ozaltin F, Bilginer Y, Gü lhan B, et al. Diagnostic validity of colchicine in patients with Familial Mediterranean fever. Clin Rheumatol. 2014;33(7):969-74. doi: 10.1007/s10067-014-2598-y
47. Ali NS, Sartori-Valinotti JC, Bruce AJ. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome. Clin Dermatol. 2016;34(4):482-6. doi: 10.1016/j.clindermatol.2016.02.021
48. Manthiram K, Lapidus S, Edwards KC. Unraveling the pathogenesis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis through genetic, immunologic, and microbiologic discoveries: an update. Curr Opin Rheumatol. 2017;29(5):493-9. doi: 10.1097/BOR.0000000000000418
49. Adrovic A, Sahin S, Barut K, Kasapcopur O. Familial Mediterranean fever and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: shared features and main differences. Rheumatol Int. 2019;39(1):29-36. doi: 10.1007/s00296-018-4105-2
50. Butbul Aviel Y, Tatour S, Gershoni Baruch R, Brik R. Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome. Semin Arthritis Rheum. 2016;45(4):471-4. doi: 10.1016/j.semarthrit.2015.07.005
51. Dusser P, Hengten V, Neven B, Kone-Paut I. Is colchicine an effective treatment in Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical adenitis (PFAPA) syndrome? Joint Bone Spine. 2016;83(4):406-11. doi: 10.1016/j.jbspin.2015.08.017
52. Gaggiano C, Rigante D, Sota J, et al. Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review. Clin Rheumatol. 2019;38(1):11-7. doi: 10.1007/s10067-018-4361-2
53. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107-19. doi: 10.1038/nrrheum.2018.3
54. Алекберова ЗС. Болезнь Великого шелкового пути: от преданий в XXI век. Научно-практическая ревматология. 2015;53(1):5-8. doi: 10.14412/1995-4484-2015-1-4
55. Алекберова ЗС. Болезнь Бехчета (лекция). Научно-практическая ревматология. 2013;51(1):52-8. doi: 10.14412/1995-4484-2013-1202
56. Gul A. Pathogenesis of Behcet's disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413-8. doi: 10.1007/s00281-015-0502-8. Epub 2015 Jun 12.
57. Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behcet's syndrome. Semin Arthritis Rheum. 2019;48(4):752-62. doi: 10.1016/j.semarthrit.2018.05.008
58. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018 ;77(6):808-18. doi: 10.1136/annrheumdis-2018-213225
59. Лисицына ТА, Алекберова ЗС, Голоева РГ. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019;57(2):133-41. doi: 10.14412/1995-4484-2019-133-141
60. Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-7. doi: 10.1007/s10067-016-3506-4
61. Fontes V, Machet L, Huttenberger B, et al. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol. 2002;129:1365-9.
62. Pakfetrat A, Mansourian A, Momen-Heravi F, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial. Clin Invest Med. 2010;33:E189-95. doi: 10.25011/cim.v33i3.13725
63. Robinson KP, Chan JJ. Colchicine in dermatology: A review. J Dermatol. 2018;59(4):278-85. doi: 10.1111/ajd.12795
64. Dasgeb B, Kornreich D, McGuinn K, et al. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178(2):350-6. doi: 10.1111/bjd.15896
65. Kuemmerle-Descner JB, Schock AL, Nansmann S, Benseler SM. Colchicine: an effective treatment option for unclassified autoinflammatory disease in children. Ann Rheum Dis. 2018. doi: 10.1136/annrheumdis-2018-eular.7473
66. Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817-25. doi: 10.1016/j.jacc.2013.08.726
67. Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018 Feb;269:262-71. doi: 10.1016/j.atherosclerosis.2017.12.027
68. Nidorf SM, Thompson PL. Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin Ther. 2019;41(1):41-8. doi: 10.1016/j.clinthera.2018.11.016
69. Adler Y, Charron P, Imazio M, et al. European Society of C 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-64. doi: 10.1093/eurheartj/ehv318
70. Cantarini L, Lopalco G, Selmi C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev. 2015;14(2):90-7. doi: 10.1016/j.autrev.2014.10.005
71. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. doi: 10.1016/S0140-6736(13)62709-9
72. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-23. doi: 10.1001/jama.2014.11026
73. Izadi Amoli A, Bozorgi A, HajHossein Talasaz A, et al. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: a randomized, placebo-controlled trial. Am Heart J. 2015;170(6):1195-201. doi: 10.1016/j.ahj.2015.09.020
74. Finkelstein Y, Shemesh J, Mahlab K, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27(8):791-4. doi: 10.1007/s00059-002-2376-5
75. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987-91. doi: 10.1001/archinte.165.17.1987
76. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-6. doi: 10.1161/CIRCULATIONAHA.105.542738
77. Imazio M, Trinchero R, Brucato A, et al. COlchicine for the prevention of the post- pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31(22):2749-54. doi: 10.1093/eurheartj/ehq319
78. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. doi: 10.7326/0003-4819-155-7-201110040-00359
79. Imazio M, Brucato A, Cemin R, et al. Investigators I. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. doi: 10.1056/NEJMoa1208536
80. Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Metaanalysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord. 2019;19(1):207. doi: 10.1186/s12872-019-1190-4
81. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34:1186-97. doi: 10.1093/eurheartj/ehs372
82. Feng D, Glockner J, Kim K, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation 2011;124:1830-7. doi: 10.1161/CIRCULATIONAHA.111.026070
83. Syed FF, Schaff HV, Oh JK. Constrictive pericarditis – a curable diastolic heart failure. Nat Rev Cardiol. 2014;11:530-44. doi: 10.1038/nrcardio.2014.100
84. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63-6. doi: 10.1038/s41577-018-0098-z
85. Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18:733-44. doi: 10.1038/s41577-018-0065-8
86. Deftereos SG, Vrachatis DA, Angelidis C, et al. The role of colchicine in treating postoperative and post-catheter ablation atrial fibrillation. Clin Ther. 2019;41(1):21-9. doi: 10.1016/j.clinthera.2018.08.008
87. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi: 10.1016/j.jacc.2009.09.009
88. Насонов ЕЛ. Попкова ТВ. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12.
89. Libby PJ. A interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Amer Coll Cardiol. 2017;70(18):2278-89. doi: 10.1016/j.jacc.2017.09.028
90. Fiolet ATL, Nidorf SM, Mosterd A, Cornel JH. Colchicine in stable coronary artery disease. Clin Ther. 2019;41(1):30-40. doi: 10.1016/j.clinthera.2018.09.011
91. Vaidya K, Martinez G, Patel S. The role of colchicine in acute coronary syndromes. Clin Ther. 2019;41(1):11-20. doi: 10.1016/j.clinthera.2018.07.023
92. Hemkens LG, Ewald H, Gloy VL, et al. Colchicine for prevention of cardiovascular events. In: Hemkens LG, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2016.
93. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027
94. Vaidya K, Arnott C, Martinez GJ, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT Coronary Angiography Study. JACC Cardiovascular Imaging 2017 Oct 14. doi: 10.1016/j.jcmg.2017.08.013
95. Deftereos S, Giannopoulos G, Angelidis C, et al. AntiInflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132:1395-403. doi: 10.1161/CIRCULATIONAHA.115.017611
96. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of lowdose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-505. doi: 10.1056/NEJMoa1912388
97. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. doi: 10.1056/NEJMoa1707914
98. Hennessy T, Soh L, Bowman M, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62-9. doi: 10.1016/j.ahj.2019.06.003
99. Nidorf SM, Fiolet ATL, Eikelboom JW, et al; LoDoCo2 Investigators. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46-56. doi: 10.1016/j.ahj.2019.09.011
100. Nguyen MT, Fernando S, Schwarz N, et al. Inflammation as a therapeutic target in atherosclerosis. J Clin Med. 2019;8(8). doi: 10.3390/jcm8081109
101. De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162-4. doi: 10.1136/ard.2009.122770
102. Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251-9. doi: 10.1093/rheumatology/ket293
103. Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52(1):111-7. doi: 10.1093/rheumatology/kes169
104. Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458-64. doi: 10.3899/jrheum.111533
105. Solomon DH, Liu C-C, Kuo I-H, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75:1674-9. doi: 10.1136/annrheumdis-2015-207984
106. Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-42. doi: 10.7326/M18-1167
107. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-14. doi: 10.3109/15563650.2010.495348
108. Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636-44. doi: 10.1136/annrheumdis-2015-207546 110. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477-89. doi: 10.1038/s41577-019-0165-0
Рецензия
Для цитирования:
Алекберова З.С., Насонов Е.Л. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2):183-190. https://doi.org/10.14412/1995-4484-2020-183-190
For citation:
Alekberova Z.S., Nasonov E.L. PROSPECTS FOR USING COLCHICINE IN MEDICINE: NEW EVIDENCE. Rheumatology Science and Practice. 2020;58(2):183-190. (In Russ.) https://doi.org/10.14412/1995-4484-2020-183-190
Просмотров: 4675
Послать статью по эл. почте 